Safety of monoclonal antibodies for the treatment of multiple sclerosis.

Article Details

Citation

Copy to clipboard

McGinley MP, Moss BP, Cohen JA

Safety of monoclonal antibodies for the treatment of multiple sclerosis.

Expert Opin Drug Saf. 2017 Jan;16(1):89-100. Epub 2016 Oct 31.

PubMed ID

27756172 [ View in PubMed

]

Abstract

INTRODUCTION: Monoclonal antibodies are a potent therapeutic approach for relapsing-remitting multiple sclerosis. This group of medications comprises diverse mechanisms of action resulting in both shared and unique adverse effects. Areas covered: The major trials and safety profiles of natalizumab, alemtuzumab, daclizumab, rituximab, and ocrelizumab are discussed. While each drug has a unique safety profile, one of the potential safety concerns for all of these drugs is infection, including for some progressive multifocal leukoencephalopathy. Other potential side effects and required monitoring for each drug are addressed. Expert opinion: The treatment of multiple sclerosis is a balance between efficacy and safety. As a group, these medications are highly effective, but not without notable safety concerns; therefore more research is needed to understand the place these medications hold in the overall treatment algorithm.

DrugBank Data that Cites this Article

Drugs

Ocrelizumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ocrelizumab	B-lymphocyte antigen CD20	Protein	Humans	Yes	Antagonist Antibody	Details